SEARCH

SEARCH BY CITATION

References

  • 1
    Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med 1999; 341: 58692.DOI: 10.1056/NEJM199908193410807
  • 2
    Bick RL. Disseminated intravascular coagulation: pathophysiological mechanisms and manifestations. Semin Thromb Hemost 1998; 24: 318.
  • 3
    Toh CH, Dennis M. Disseminated intravascular coagulation: old disease, new hope. BMJ 2003; 327: 9747.
  • 4
    Takahashi H, Tatewaki W, Wada K, Hanano M, Shibata A. Thrombin vs. plasmin generation in disseminated intravascular coagulation associated with various underlying disorders. Am J Hematol 1990; 33: 905.
  • 5
    Asakura H, Jokaji H, Saito M, Uotani C, Kumabashiri I, Morishita E, Yamazaki M, Aoshima K, Matsuda T. Study of the balance between coagulation and fibrinolysis in disseminated intravascular coagulation using molecular markers. Blood Coagul Fibrinolysis 1994; 5: 82932.
  • 6
    Matsuda T, Asakura H, Ito K, Saito M, Jokaji Y, Uotani C, Kumabashiri I. Changes in levels of t-PA and alpha 2PI-plasmin complex in plasma in patients with DIC. Thromb Res Suppl 1988; 8: 14351.DOI: 10.1016/0049-3848(88)90163-6
  • 7
    Dombret H, Scrobohaci ML, Daniel MT, Miclea JM, Castaigne S, Chomienne C, Fenaux P, Degos L. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): effect of all-trans retinoic acid (ATRA) therapy. Leukemia 1995; 9: 1924.
  • 8
    Paramo JA, Fernandez Diaz FJ, Rocha E. Plasminogen activator inhibitor activity in bacterial infection. Thromb Haemost 1988; 59: 4514.
  • 9
    Levi M, De Jonge E, Van Der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis 2003; 16: 437.DOI: 10.1023/B:THRO.0000014592.27892.11
  • 10
    Forstermann U, Boissel JP, Kleinert H. Expressional control of the ‘constitutive’ isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998; 12: 77390.
  • 11
    Geller DA, Billiar TR. Molecular biology of nitric oxide synthases. Cancer Metastasis Rev 1998; 17: 723.DOI: 10.1023/A:1005940202801
  • 12
    Kroncke KD, Fehsel K, Kolb-Bachofen V. Inducible nitric oxide synthase in human diseases. Clin Exp Immunol 1998; 113: 14756.DOI: 10.1046/j.1365-2249.1998.00648.x
  • 13
    Szabo C, Southan GJ, Thiemermann C. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci USA 1994; 91: 124726.
  • 14
    Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol 1998; 18: 17719.
  • 15
    Gerlach M, Keh D, Bezold G, Spielmann S, Kurer I, Peter RU, Falke KJ, Gerlach H. Nitric oxide inhibits tissue factor synthesis, expression and activity in human monocytes by prior formation of peroxynitrite. Intensive Care Med 1998; 24: 1199208.DOI: 10.1007/s001340050745
  • 16
    Yang Y, Loscalzo J. Regulation of tissue factor expression in human microvascular endothelial cells by nitric oxide. Circulation 2000; 101: 21448.
  • 17
    Perez-Ruiz A, Montes R, Velasco F, Lopez-Pedrera C, Antonio Paramo J, Orbe J, Hermida J, Rocha E. Regulation by nitric oxide of endotoxin-induced tissue factor and plasminogen activator inhibitor-1 in endothelial cells. Thromb Haemost 2002; 88: 10605.
  • 18
    Fiorucci S, Mencarelli A, Meneguzzi A, Lechi A, Morelli A, Del Soldato P, Minuz P. NCX-4016 (NO-aspirin) inhibits lipopolysaccharide-induced tissue factor expression in vivo: role of nitric oxide. Circulation 2002; 106: 31205.
  • 19
    Asakura H, Okudaira M, Yoshida T, Ontachi Y, Yamazaki M, Morishita E, Miyamoto K, Nakao S. Induction of vasoactive substances differs in LPS-induced and TF-induced DIC models in rats. Thromb Haemost 2002; 88: 6637.
  • 20
    Moore WM, Webber RK, Jerome GM, Tjoeng FS, Misko TP, Currie MG. L-N6-(1-iminoethyl) lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 1994; 37: 38868.DOI: 10.1021/jm00049a007
  • 21
    Schwartz D, Mendonca M, Schwartz I, Xia Y, Satriano J, Wilson CB, Blantz RC. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J Clin Invest 1997; 100: 43948.
  • 22
    Pelzer H, Schwarz A, Heimburger N. Determination of human thrombin–antithrombin III complex in plasma with an enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 1016.
  • 23
    Nims RW, Cook JC, Krishna MC, Christodoulou D, Poore CM, Miles AM, Grisham MB, Wink DA. Colorimetric assays for nitric oxide and nitrogen oxide species formed from nitric oxide stock solutions and donor compounds. Methods Enzymol 1996; 268: 93105.
  • 24
    Suzuki N, Matsumoto H, Kitada C, Masaki T, Fujino M. A sensitive sandwich-enzyme immunoassay for human endothelin. J Immunol Methods 1989; 118: 24550.DOI: 10.1016/0022-1759(89)90012-4
  • 25
    Kawasaki H, Hayashi K, Awai M. Disseminated intravascular coagulation (DIC). Immunohistochemical study of fibrin-related materials (FRMs) in renal tissues. Acta Pathol Jpn 1987; 37: 7784.
  • 26
    Stamler JS, Singel DJ, Loscalzo J. Biochemistry of nitric oxide and its redox-activated forms. Science 1992; 258: 1898902.
  • 27
    Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 1995; 38: 87104.
  • 28
    Mendelsohn ME, O'Neill S, George D, Loscalzo J. Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. J Biol Chem 1990; 265: 1902834.
  • 29
    Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001; 86: 132730.
  • 30
    Kaddoura S, Curzen NP, Evans TW, Firth JD, Poole-Wilson PA. Tissue expression of endothelin-1 mRNA in endotoxaemia. Biochem Biophys Res Commun 1996; 218: 6417.DOI: 10.1006/bbrc.1996.0115
  • 31
    Lechleitner P, Genser N, Mair J, Maier J, Artner-Dworzak E, Dienstl F, Puschendorf B. Plasma immunoreactive endothelin in the acute and subacute phases of myocardial infarction in patients undergoing fibrinolysis. Clin Chem 1993; 39: 9559.
  • 32
    Battistelli S, Billi M, Manasse G, Vittoria A, Roviello F, Forconi S. Behavior of circulating endothelin-1 in a group of patients with acute myocardial infarction. Angiology 1999; 50: 62938.
  • 33
    Saetre T, Hoiby EA, Aspelin T, Lermark G, Egeland T, Svindland A, Lyberg T. Aminoethyl-isothiourea inhibits the increase in plasma endothelin-1 caused by serogroup A streptococci and prolongs survival in rat peritoneal sepsis. Shock 2001; 15: 44652.
  • 34
    Hollenberg SM, Piotrowski MJ, Parrillo JE. Nitric oxide synthase inhibition reverses arteriolar hyporesponsiveness to endothelin-1 in septic rats. Am J Physiol 1997; 272 (3 Part 2): R96974.